Shield Therapeutics plc (STX) - Total Liabilities

Latest as of June 2025: GBX76.96 Million GBX ≈ $9.36K USD

Based on the latest financial reports, Shield Therapeutics plc (STX) has total liabilities worth GBX76.96 Million GBX (≈ $9.36K USD) as of June 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check STX asset resilience ratio to evaluate the company's liquid asset resilience ratio.

Shield Therapeutics plc - Total Liabilities Trend (2013–2024)

This chart illustrates how Shield Therapeutics plc's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see Shield Therapeutics plc assets under control.

Shield Therapeutics plc Competitors by Total Liabilities

The table below lists competitors of Shield Therapeutics plc ranked by their total liabilities.

Company	Country	Total Liabilities
Kuchai Develop Bhd KLSE:2186	Malaysia	RM1.73 Million
DBT SA PA:ALDBT	France	€22.79 Million
Asian Television Network International Ltd V:SAT	Canada	CA$6.63 Million
OSX Brasil S.A SA:OSXB3	Brazil	R$10.90 Billion
Cora Gold Limited LSE:CORA	UK	GBX282.00K
C3is Inc. NASDAQ:CISS	USA	$3.39 Million
InsuraGuest Technologies Inc V:ISGI	Canada	CA$703.54K
Ivory Properties Group Bhd KLSE:5175	Malaysia	RM206.09 Million

Liability Composition Analysis (2013–2024)

This chart breaks down Shield Therapeutics plc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See Shield Therapeutics plc balance sheet independence to measure how much of total assets are equity-financed.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric	Value	Description
Current Ratio	0.83	Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio	N/A	More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio	N/A	Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity	-5.18	Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets	1.24	Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Shield Therapeutics plc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Shield Therapeutics plc (2013–2024)

The table below shows the annual total liabilities of Shield Therapeutics plc from 2013 to 2024.

Year	Total Liabilities	Change
2024-12-31	GBX46.95 Million ≈ $5.71K	+77.25%
2023-12-31	GBX26.49 Million ≈ $3.22K	+59.11%
2022-12-31	GBX16.65 Million ≈ $2.03K	+392.51%
2021-12-31	GBX3.38 Million ≈ $411.25	+50.09%
2020-12-31	GBX2.25 Million ≈ $274.00	-46.05%
2019-12-31	GBX4.17 Million ≈ $507.86	+41.44%
2018-12-31	GBX2.95 Million ≈ $359.05	-21.58%
2017-12-31	GBX3.76 Million ≈ $457.85	-5.64%
2016-12-31	GBX3.99 Million ≈ $485.22	-81.45%
2015-12-31	GBX21.50 Million ≈ $2.62K	+11.48%
2014-12-31	GBX19.29 Million ≈ $2.35K	+139.66%
2013-12-31	GBX8.05 Million ≈ $979.21	--

About Shield Therapeutics plc

LSE:STX UK Drug Manufacturers - Specialty & Generic

Market Cap

$617.24K

GBX5.07 Billion GBX

Market Cap Rank

#30962 Global

#894 in UK

Share Price

GBX4.75

Change (1 day)

+0.00%

52-Week Range

GBX3.70 - GBX12.20

All Time High

GBX185.02